Hims & Hers Health (HIMS) stock surged nearly 6% after a report indicated the FDA is moving to lift restrictions on peptides. The agency plans to allow compounding pharmacies to manufacture over a dozen injectable peptides, reversing a 2023 ban. Since Hims & Hers offers compounded medications, this regulatory shift is viewed as a positive catalyst for the telehealth provider.